Therefore, the relative role of a direct blockade of glucagon signaling in the liver and the indirect effects of GCGR blocker treatment leading to an elevation of plasma GLP-1 on the improvement of hyperglycemia in type 2 diabetes remains to be clarified. This evidence concerns the gene GCG and type 2 diabetes mellitus.